ストックスクリーナーアプリを入手
222.47
0.40%
0.88
アフターアワーズ：
222.47
前日終値:
$221.59
開ける：
$223.31
24時間の取引高:
5.94M
Relative Volume:
0.94
時価総額：
$393.06B
収益：
$62.82B
当期純損益:
$3.60B
株価収益率:
109.73
EPS:
2.0274
ネットキャッシュフロー:
$19.98B
1週間 パフォーマンス:
-1.31%
1か月 パフォーマンス:
+5.74%
6か月 パフォーマンス:
-0.54%
1年 パフォーマンス:
+16.56%
1日の値動き範囲:
$219.15
$223.50
1週間の範囲:
$219.15
$228.40
52週間の値動き範囲:
$181.73
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Compare ABBV vs LLY, JNJ, NVS, MRK
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
222.47 | 391.50B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,122.50 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
235.18 | 567.28B | 96.36B | 21.04B | 17.80B | 8.6488 |
NVS
Novartis Ag Adr
|
150.93 | 289.19B | 54.66B | 13.58B | 16.05B | 7.0171 |
MRK
Merck Co Inc
|
115.17 | 283.78B | 65.51B | 8.93B | 14.12B | 3.5532 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-30 | アップグレード | BofA Securities | Neutral → Buy |
| 2026-04-21 | 開始されました | Canaccord Genuity | Buy |
| 2026-02-25 | 開始されました | RBC Capital Mkts | Outperform |
| 2026-02-20 | 開始されました | Barclays | Overweight |
| 2026-01-08 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | 再開されました | UBS | Neutral |
| 2025-12-10 | アップグレード | HSBC Securities | Hold → Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-11-04 | ダウングレード | DZ Bank | Buy → Hold |
| 2025-10-14 | ダウングレード | Erste Group | Buy → Hold |
| 2025-10-01 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-09-17 | アップグレード | Berenberg | Hold → Buy |
| 2025-08-12 | 再開されました | Piper Sandler | Overweight |
| 2025-08-07 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-05 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-04 | アップグレード | Argus | Hold → Buy |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-06-05 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-05-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-01-29 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | ダウングレード | HSBC Securities | Buy → Hold |
| 2023-12-11 | アップグレード | Goldman | Neutral → Buy |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-30 | アップグレード | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-07-25 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-04-05 | ダウングレード | Argus | Buy → Hold |
| 2023-03-01 | 開始されました | Guggenheim | Buy |
| 2023-02-22 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-11-08 | ダウングレード | Societe Generale | Buy → Hold |
| 2022-08-01 | ダウングレード | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Underperform |
| 2022-05-06 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-02-28 | ダウングレード | UBS | Buy → Neutral |
| 2022-02-03 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-03 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-03 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-03 | 繰り返されました | Goldman | Neutral |
| 2022-01-13 | 開始されました | Redburn | Buy |
| 2022-01-12 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-11-23 | アップグレード | Societe Generale | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-04-07 | 再開されました | RBC Capital Mkts | Outperform |
| 2020-11-10 | 再開されました | Bernstein | Outperform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-06-23 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | アップグレード | Argus | Hold → Buy |
| 2020-05-18 | 再開されました | BofA/Merrill | Neutral |
| 2020-05-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 再開されました | Morgan Stanley | Overweight |
| 2020-04-20 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-06 | 開始されました | Mizuho | Buy |
| 2020-01-07 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 繰り返されました | Cowen | Outperform |
| 2019-09-26 | アップグレード | Citigroup | Neutral → Buy |
| 2019-08-20 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 開始されました | Goldman | Neutral |
| 2019-04-29 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
すべてを表示
Abbvie Inc (ABBV) 最新ニュース
AbbVie Inc. stock underperforms Monday when compared to competitors - MarketWatch
AbbVie Stock in 2026: Skyrizi and Rinvoq Drive 12% Revenue Growth as Margins Begin to Inflect - TIKR.com
S&P upgrades AbbVie outlook on immunology drug growth By Investing.com - Investing.com Australia
S&P upgrades AbbVie outlook on immunology drug growth - Investing.com
AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 Trade Ideas — BCBA:ABBV.CI - TradingView
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) - GlobeNewswire Inc.
AbbVie (ABBV) Stock Weighs DCF Upside Against Elevated P/E At US$227.73 - Yahoo Finance
AbbVie (ABBV) Receives a Hold from Citi - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: C4 Therapeutics (CCCC), AbbVie (ABBV) - The Globe and Mail
AbbVie (ABBV) Rises Higher Than Market: Key Facts - Yahoo Finance
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
NYLIM VP Epoch U.S. Equity Yield Portfolio's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie Says Nine-Year Data Reinforces Venetoclax Benefit In Leukemia Patients - Benzinga
AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy (NYSE:ABBV) - Seeking Alpha
AbbVie presents Phase III venetoclax data in first-line CLL - The Pharma Letter
AbbVie reports nine-year CLL14 trial data for Venclexta at EHA 2026 - grafa.com
6,889 Shares in AbbVie Inc. $ABBV Bought by Winning Points Advisors LLC - MarketBeat
Woodley Farra Manion Portfolio Management Inc. Has $5.30 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend. - Yahoo Finance
Logan Capital Management Inc. Sells 8,592 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results - Investing News Network
AbbVie (ABBV) Reveals Promising Phase 3 Data on CLL Treatment - GuruFocus
AbbVie Inc. $ABBV Shares Sold by Sepio Capital LP - MarketBeat
Nuveen LLC Grows Stock Position in AbbVie Inc. $ABBV - MarketBeat
SmartHarvest Portfolios LLC Buys Shares of 9,927 AbbVie Inc. $ABBV - MarketBeat
AbbVie presents nine-year CLL14 trial results at EHA congress By Investing.com - Investing.com Canada
Leukemia patients go 7.6 years before next treatment in AbbVie trial - Stock Titan
Barclays Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $275 - Moomoo
Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax - Barchart.com
AbbVie Loses Colorado 340B Drug Pricing Law Challenge - Law360
AbbVie: Growth-Pharma Profile At A Value-Pharma Price (NYSE:ABBV) - Seeking Alpha
Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225 - Yahoo Finance
Is AbbVie Inc. (ABBV) A Good Stock To Buy Now? - Insider Monkey
Will Skyrizi & Rinvoq Continue to Drive AbbVie's Topline Through 2026? - TradingView
Zions Bancorporation National Association UT Sells 12,395 Shares of AbbVie Inc. $ABBV - MarketBeat
M Holdings Securities Inc. Takes Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie, Devon Energy And More On CNBC's 'Final Trades' - Benzinga
AbbVie Inc. $ABBV Shares Acquired by Wellspring Financial Advisors LLC - MarketBeat
Saturna Capital Corp Purchases 31,143 Shares of AbbVie Inc. $ABBV - MarketBeat
Smithbridge Asset Management Inc. DE Buys 18,364 Shares of AbbVie Inc. $ABBV - MarketBeat
Signet Private Wealth LLC Invests $1.20 Million in AbbVie Inc. $ABBV - MarketBeat
Townsquare Capital LLC Has $6.98 Million Stake in AbbVie Inc. $ABBV - MarketBeat
Illinois Municipal Retirement Fund Lowers Position in AbbVie Inc. $ABBV - MarketBeat
Janney Montgomery Scott LLC Grows Position in AbbVie Inc. $ABBV - MarketBeat
Dorsey & Whitney Trust CO LLC Reduces Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
HUTNER CAPITAL MANAGEMENT INC's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie Inc. stock (US00287Y1091): investors eye Skyrizi/Humira dynamics after recent data update - AD HOC NEWS
Final Trades: AbbVie, Devon Energy and the 2-Year and 10-Year Treasuries - CNBC
AbbVie Receives Complete Response Letter From FDA For TrenibotE Biologics License Application - marketscreener.com
Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics - AbbVie News Center
AbbVie's migraine drug cleared for migraine attacks on NHS - pharmaphorum
Abbvie Inc (ABBV) 財務データ
収益
当期純利益
現金流量
EPS
0.42%
0.23%
大文字化:
|
ボリューム (24 時間):